EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act

Julie A Patterson, James Motyka, Rayan Salih, Robert Nordyke, John M O'Brien, Jonathan D Campbell

Therapeutic Innovation & Regulatory Science · 2025-01 · 59 (1) · 102-111

DOI: 10.1007/s43441-024-00706-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 06.10.2024. Verfasst von Julie A Patterson und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Pharmaceutical Council, 1717 Pennsylvania AVE NW Ste 800, Washington, DC, 20006, USA. jpatterson@npcnow.org. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents, United States Food and Drug Administration. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recent research has raised questions about potential unintended consequences of the Inflation Reduction Act’s Drug Price Negotiation Program (DPNP), suggesting that the timelines introduced by the law may reduce manufacturer incentives to invest in post-approval research towards additional indications. Given the role of multiple indications in expanding treatment options in patients with cancer, IRA-related changes to development incentives are especially relevant in oncology. This study aimed to describe heterogeneous drug-level trajectories and timelines of subsequent indications in a cohort of recently approved, multi-indication oncology drugs, including overall, across subgroups of drugs characterized by the timing and pace of additional indications, and by drug type (i.e., small molecule vs. biologic).

Methods

This cross-sectional study evaluated oncology drugs first approved by the FDA from 2008 to 2018 and later approved for one or more additional indications. Numbers, types, and approval timelines of subsequent indications were recorded at the drug level, with drugs grouped by quartile based on the pacing of post-approval development (i.e., “rapid pace” to “measured pace”).

Results

Multi-indication oncology drugs ( N = 56/86, 65.1%) had one or more subsequent indication approved in a new: cancer type (60.7%), line of treatment (50.0%), combination (41.1%), mutation (32.1%), or stage (28.6%). The median time between FDA approvals for indications increased from 0.6 years (IQR: 0.48, 0.74) in the “rapid pace” group to 1.6 years (IQR: 1.32, 1.66), 2.4 years (IQR: 2.29, 2.61), and 4.9 years (IQR: 3.43, 6.23) in the “moderate,” “measured-moderate,” and “measured” pace groups, respectively. Drugs in the “rapid pace” group often received their first subsequent indication approval within 9 months of initial approval (median: 0.7 years; IQR: 0.54, 1.59), whereas the “measured pace” group took a median of 5.7 years (IQR: 3.43, 6.98). Across all multi-indication drugs, the median time to the most recent approval for a subsequent indication was 5.5 years (IQR: 3.18, 7.95). One quarter (25%) of drugs were approved for their most recent subsequent indication after the time at which they would be DPNP-eligible.

Conclusion

Approval histories of new oncology drugs demonstrate the role of post-approval indications in expanding treatment options towards new cancer types, stages, lines, combinations, and mutations. Heterogeneous clinical development pathways provide insights into potential unintended consequences of IRA-related changes surrounding post-approval research and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsUnited States Food and Drug AdministrationCross-Sectional StudiesHumansUnited StatesTime FactorsNeoplasmsDrug Costs

Stichwörter der Autor:innen

Drug developmentHealth policyInflation reduction actOncologyUS food and drug administration

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • National Pharmaceutical Council, 1717 Pennsylvania AVE NW Ste 800, Washington, DC, 20006, USA. jpatterson@npcnow.org.
  • National Pharmaceutical Council, 1717 Pennsylvania AVE NW Ste 800, Washington, DC, 20006, USA.
  • Petauri, LLC, formerly National Pharmaceutical Council, Washington, DC, USA.

Zitieren

APA

Patterson, J. A., Motyka, J., Salih, R., Nordyke, R., O'Brien, J. M., & Campbell, J. D. (2025). Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act. Therapeutic Innovation & Regulatory Science, 59(1), 102-111. https://doi.org/10.1007/s43441-024-00706-6

Vancouver

Patterson JA, Motyka J, Salih R, Nordyke R, O'Brien JM, Campbell JD. Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act. Therapeutic Innovation & Regulatory Science. 2025;59(1):102-111. doi:10.1007/s43441-024-00706-6

BibTeX
@article{Patterson2025,
  author = {Patterson, Julie A and Motyka, James and Salih, Rayan and Nordyke, Robert and O'Brien, John M and Campbell, Jonathan D},
  title = {Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  volume = {59},
  number = {1},
  pages = {102--111},
  doi = {10.1007/s43441-024-00706-6}
}
Kostenlos starten →